Literature DB >> 8340756

CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation.

R L Camp1, A Scheynius, C Johansson, E Puré.   

Abstract

The in vivo administration of certain monoclonal antibodies (mAbs) against the adhesion receptor, CD44, into normal mice induces both a modulation of CD44 from the surface of peripheral lymphocytes, and a concomitant increase in the amount of soluble CD44 in the serum. CD44-negative lymphocytes isolated from anti-CD44-treated mice exhibit normal homing patterns upon adoptive transfer, and are capable of reexpressing CD44 upon activation. The treatment of haptensensitized mice with anti-CD44 mAb inhibits their ability to mount a cutaneous delayed-type hypersensitivity (DTH) response within the first 24 h after hapten challenge. This inhibition reflects a block in both the edema and leukocyte infiltration of the cutaneous site of DTH, whereas the extravasation and accumulation of leukocytes in the draining lymph nodes progress normally. After 72 h, the leukocytes that extravasate into the site of antigen challenge express CD44. These results indicate that CD44 is not necessary for normal leukocyte circulation but is required for leukocyte extravasation into an inflammatory site involving nonlymphoid tissue.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8340756      PMCID: PMC2191099          DOI: 10.1084/jem.178.2.497

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  42 in total

1.  Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand.

Authors:  V Bazil; V Horejsí
Journal:  J Immunol       Date:  1992-08-01       Impact factor: 5.422

2.  Tolerance and contact sensitivity to DNFB in mice. I. In vivo detection by ear swelling and correlation with in vitro cell stimulation.

Authors:  P Phanuphak; J W Moorhead; H N Claman
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

3.  Significance of CD44 gene products for cancer diagnosis and disease evaluation.

Authors:  Y Matsumura; D Tarin
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

4.  Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1.

Authors:  A Scheynius; R L Camp; E Puré
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

5.  The cellular infiltrate in contact hypersensitivity to picryl chloride in the mouse.

Authors:  G Roupe; B Ridell
Journal:  Acta Derm Venereol       Date:  1979       Impact factor: 4.437

6.  Participation in normal immune responses of a metastasis-inducing splice variant of CD44.

Authors:  R Arch; K Wirth; M Hofmann; H Ponta; S Matzku; P Herrlich; M Zöller
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

Review 7.  Rational immunotherapy with interleukin 2.

Authors:  G Kaplan; Z A Cohn; K A Smith
Journal:  Biotechnology (N Y)       Date:  1992-02

8.  Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44.

Authors:  G Koopman; K H Heider; E Horst; G R Adolf; F van den Berg; H Ponta; P Herrlich; S T Pals
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

9.  A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps.

Authors:  K H Heider; M Hofmann; E Hors; F van den Berg; H Ponta; P Herrlich; S T Pals
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

10.  Requirements for hyaluronic acid binding by CD44: a role for the cytoplasmic domain and activation by antibody.

Authors:  J Lesley; Q He; K Miyake; A Hamann; R Hyman; P W Kincade
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  49 in total

Review 1.  Adhesion molecule cascades direct lymphocyte recirculation and leukocyte migration during inflammation.

Authors:  D A Steeber; T F Tedder
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice.

Authors:  Qin Wang; Priit Teder; Nancy P Judd; Paul W Noble; Claire M Doerschuk
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  CD44--a sticky target for asthma.

Authors:  Marc E Rothenberg
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 4.  Forms and functions of CD44.

Authors:  G Borland; J A Ross; K Guy
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

5.  CD44 and hyaluronan-dependent rolling interactions of lymphocytes on tonsillar stroma.

Authors:  R A Clark; R Alon; T A Springer
Journal:  J Cell Biol       Date:  1996-08       Impact factor: 10.539

6.  Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion.

Authors:  M Mohamadzadeh; H DeGrendele; H Arizpe; P Estess; M Siegelman
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

7.  CD44: one ligand, two functions.

Authors:  A Aruffo
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

8.  Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody.

Authors:  L Weiss; S Slavin; S Reich; P Cohen; S Shuster; R Stern; E Kaganovsky; E Okon; A M Rubinstein; D Naor
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

9.  Cathelicidin antimicrobial peptides inhibit hyaluronan-induced cytokine release and modulate chronic allergic dermatitis.

Authors:  Yasuhide Morioka; Kenshi Yamasaki; Donald Leung; Richard L Gallo
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

10.  Stem cells, inflammation and allergy.

Authors:  Marie-Renee Blanchet; Kelly M McNagny
Journal:  Allergy Asthma Clin Immunol       Date:  2009-12-07       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.